UNSPSC 51413208: Trimetazidine dihydrochloride

This classification denotes a cardiotonic agent with the molecular formula C14H22N2O3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48V6723Z1P, chemically known as 1-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride but more generally known as trimetazidine dihydrochloride, which bears US NIH Compound Identifier 83201. European Medicines Agency schedules Trimetazidine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12374MIG.

Most nations, for tariff and trade purposes, schedule trimetazidine dihydrochloride under HS 29335995. As of Q4 2014, TRIMETAZIDINE DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: COC1CCC(C(C1OC)OC)CN2CCNCC2.CL.CL.

UNSPSC 51413208 Trimetazidine dihydrochloride is a Commodity code covering a single active pharmaceutical ingredient used in cardiac care, but state and local governments procure it as part of broader advanced life support medication bundles rather than as an isolated drug substance. Recent solicitations show demand from emergency services and health agencies for ready-to-administer injectable medications in clinical concentrations, supplied with full regulatory documentation and expiration guarantees. The issuing bodies reflect the fragmented structure of state and local healthcare procurement: city fire rescue services (Tampa Fire Rescue), state health and human services commissions operating pharmacy benefit programs (Texas HHS), and multi-state cooperative purchasing alliances coordinating pharmaceutical acquisition across state and local facilities (Minnesota Department of Administration through MMCAP). All three buyer types emphasize supply chain compliance, FDA certification, cGMP manufacturing practices, and Drug Supply Chain Security Act (DSCSA) attestation, indicating that pharmaceutical procurement at this tier prioritizes regulatory rigor and vendor reliability over price alone.

Activity under the code concentrates in the South (Florida and Texas) and Upper Midwest (Minnesota and participating Oregon facilities through a cooperative), with the most recent opportunities spanning April 2026 back to January 2026. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, for advanced life support medications including labetalol, epinephrine, adenosine, and diltiazem vials with a due date of April 8, 2026 (already closed as of today's date), carrying a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount capped at $10,000 and an estimated contract value of $40,000. The Texas Health and Human Services Commission posted RFI HHS0017013 in early April 2026 to explore direct-to-manufacturer prescription distribution models, signaling state-level interest in bypassing traditional PBM channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with proposals due March 26, 2026, emphasizing price competitiveness (75 percent evaluation weight), cGMP and DSCSA compliance, and EDI capability; contract terms run two years for new vendors effective July 1, 2026.